Foghorn Therapeutics Inc (FHTX)
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker FHTX. The company focuses on discovering and developing medicines for genetically defined vulnerabilities in the chromatin regulatory system. Its proprietary Gene Traffic Control platform is used to help identify and validate potential drug targets. Foghorn is advancing programs across several cancer areas, including mutant non-small cell lung cancer, endometrial, cervical, ovarian and bladder cancers, diffuse large B-cell lymphoma, and forms of acute myeloid leukemia and myelodysplastic syndrome. The company also has a collaboration with Eli Lilly and Company related to FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics was incorporated in 2015 and is based in Watertown, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-FHTX
|
$4.67
|
10.1% Upside
|
Fair
|
$11.44
|
169.9% Upside
|
Bargain
|
Fair
|
0.0%
|
November 10, 2026
|
6.7x
|
251.8 M
|
122 M
|
14.9%
|
47.3%
|
-4.2
|
130.5%
|
